Fig. 2

The network plots. (A First-line PFS network plot of therapies. B First-line PFS network plot of mechanisms. C First-line OS network plot of therapies. D First-line OS network plot of mechanisms. E Second/further-lines PFS network plot of therapies. F Second/further-lines PFS network plot of mechanisms. G Second/further-lines OS network plot of therapies. H Second/further-lines OS network plot of mechanisms). Abbreviations: Abema, Abemaciclib; ALP, Alpelisib; ANA, Anastrozole; BEV, Bevacizumab; CAP, Capivasertib; ENT, Entinostat; EXE, Exemestane; EVE, Everolimus; FUL, Fulvestrant; Palbo, Palbociclib; Ribo, Ribociclib; AI, Aromatase inhibitor; AKTi, AKT inhibitor; Anti-VEGF, Anti-vascular endothelial growth factor; CDK4/6i, Cyclin-dependent kinase 4 and 6 inhibitors; EGFRi: Epidermal growth factor receptor inhibitor; HDACi, Histone deacetylase inhibitor; ICI, Immune checkpoint inhibitors; mTORi, Mammalian target of rapamycin inhibitor; Pi, Protease inhibitor; PI3Ki, Phosphatidylinositol 3-kinase inhibitor; SERD, Selective estrogen receptor degrader